Google has dedicated more than 100 employees from multiple disciplines to making its vision of nanotechnology-enabled detection of cancer and other diseases a reality. Any tangible product resulting from this ambitious effort is at least 5 to 7 years away.
Established point-of-care diagnostics company Welch Allyn has partnered with wearables startup Gentag to develop medical devices that use wireless sensors.
Alere continued down the path of deleveraging and refocusing on its core competency in diagnostics with the sale of its Alere Health unit to Optum, a part of the insurance company UnitedHealth Group for $600 million.
The U.S. Food and Drug Administration has given a temporary thumbs up to Ebola test FilmArray BioThreat-E from BioFire Defense, a bioMérieux company. The test offers results in one hour rather than the one to two days required by existing methods.
Startup Gamma Medica is aiming to improve the odds and lower the cost of effective imaging of dense breast tissue with its molecular breast imaging tool. Now, it's gained a cash infusion of $11.5 million to aid in its commercialization efforts.
U.K.-based Enigma Diagnostics inked a deal with a Chinese biotech outfit and roped in $50 million to support development of its innovative molecular diagnostic system and gain headway in the country's rapidly growing med tech market.
St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.
Preimplantation genetic screening and diagnostics provider Reprogenetics is partnering with Illumina to use its next-generation sequencing tech in its analysis of embryos and infertility.
Minnesota's Mayo Clinic is suing one of its former top executives for misappropriation of trade secrets as part of a plan to work for competitor Quest Diagnostics following a false retirement.
Researchers have identified a hormone that is associated with fructose, fibroblast growth factor 21 (FGF21), which increases rapidly in the blood after fructose ingestion. High FGF21 levels in the blood are associated with obesity, insulin resistance and nonalcoholic fatty liver disease in both humans and animals.